GPBAR1 and experimental autoimmune encephalomyelitis: The supplementation of tauroursodeoxycholic acid (TUDCA) has been demonstrated to reduce the severity of disease through G protein-coupled bile acid receptor 1 (GPBAR1) in experimental autoimmune encephalomyelitis (EAE) [138].